Guidelines for Using Doxepin for Insomnia

Introduction to Doxepin for Insomnia

The American Academy of Sleep Medicine recommends doxepin at low doses (3 mg and 6 mg) specifically for the treatment of sleep maintenance insomnia in adults, but not for sleep onset insomnia 1, 2, 3

The recommended dosage range for treating insomnia is low-dose doxepin (3 mg and 6 mg), which is significantly lower than the doses used for depression (25-150 mg) 4, 5
For elderly or debilitated patients, starting with the lowest effective dose (3 mg) is recommended 5, 6
Administration should be 30 minutes before bedtime on an empty stomach for maximum effectiveness 7

Doxepin significantly improves sleep maintenance parameters, including Wake After Sleep Onset (WASO), with a reduction of 22-23 minutes compared to placebo 4, 5, 6
Doxepin improves Total Sleep Time (TST) by 26-32 minutes at 3 mg and 6 mg doses 8, 5, 9
Doxepin improves Sleep Efficiency (SE) by 6.78% at 3 mg and 7.06% at 6 mg 6, 9
Doxepin is less effective for sleep onset issues, with minimal improvement in Sleep Latency (SL) at 3 mg (-2.30 min) and modest improvement at 6 mg (-5.29 min) 5, 6

Doxepin is not recommended during pregnancy or nursing 7
Use with caution in patients with signs/symptoms of depression, compromised respiratory function, or hepatic heart failure 7
Potential side effects include mild somnolence, headache, and diarrhea 5, 9

The American Academy of Sleep Medicine suggests that doxepin should not be prescribed for sleep onset insomnia when other agents may be more appropriate 1, 2
Failing to distinguish between sleep maintenance insomnia (where doxepin excels) versus sleep onset insomnia (where doxepin has limited efficacy) is a common pitfall 5, 6

The American College of Physicians identifies low-dose doxepin as a preferred first-line option specifically for sleep maintenance insomnia with a favorable safety profile, and it can be used for up to 12 weeks with maintained efficacy and no tolerance 10
Combining low-dose doxepin with mirtazapine and quetiapine requires monitoring but is not contraindicated, and the additive sedation may actually be beneficial for sleep maintenance without increasing fall risk at the 3 mg doxepin dose 10

Low-dose doxepin can be combined with Cognitive Behavioral Therapy for Insomnia (CBT-I) for superior long-term outcomes, and attempt gradual withdrawal after 9 months to reassess need 10

The American College of Physicians recommends low-dose doxepin (3-6 mg) for sleep maintenance insomnia in elderly patients with dementia, after attempting cognitive behavioral therapy for insomnia (CBT-I) first, with careful consideration of the patient's anticholinergic burden and fall risk 11, 12

CBT-I must be initiated before or concurrently with any pharmacological treatment, as it provides superior long-term outcomes with effects sustained for up to 2 years without medication-related risks, according to the American Academy of Sleep Medicine 11

Doxepin specifically improves sleep maintenance, not sleep onset, in elderly patients with dementia, as reported by the American College of Physicians 11, 12
The American College of Physicians guidelines recommend against using benzodiazepines (temazepam, diazepam, lorazepam) in dementia patients, due to increased dementia progression, falls, cognitive impairment, and dependency risks 12

The American Academy of Sleep Medicine advises against using antihistamines (diphenhydramine, hydroxyzine) in dementia patients, due to anticholinergic effects that can accelerate dementia progression and cause confusion, urinary retention, and delirium 12

The recommendation for low-dose doxepin is based on low to moderate quality evidence from the American College of Physicians guidelines, and high-quality synthesis from the American Academy of Sleep Medicine, demonstrating efficacy in older adults (≥65 years) with primary insomnia 11, 12